Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity available at the Rutherford Cancer Centre North West in Liverpool from late 2020.
Dr Hans van der Voet is a senior consultant clinical oncologist and radiotherapy lead at the James Cook University Hospital in Middlesbrough. He qualified at the University of Amsterdam Medical School in 1989 and started his radiotherapy training at The Netherlands Cancer Institute/Anthony van Leeuwenhoek Hospital in Amsterdam in 1990. He took a year out from training to do a clinical fellowship in bladder cancer at the Christie Hospital in Manchester from 1993. After completion of specialist training at the NCI/AvL in 1995, he returned to the Christie hospital as a senior registrar. In 1997 he took up a position as consultant clinical oncologist in Middlesbrough.
Dr Hans van der Voet specialises and manages a busy practice in urological cancers, lower gastrointestinal cancer including anal cancer and sarcoma. He was instrumental in establishing image guided radiotherapy and subsequently intensity modulated radiotherapy in Middlesbrough. He has a fast experience in the treatment of prostate cancer including stereotactic radiotherapy.
Dr Hans van der Voet also has an interest in providing radiotherapy for the treatment of early Dupuytren’s disease and has been treating patients for this condition since 2013. Dr van der Voet is a member of the Northern Cancer Alliance Radiotherapy Expert Advisory Group.
Proton Beam Therapy
This consultant has received training from the Rutherford Cancer Centres in the delivery of proton beam therapy. The programme, Proton Therapy Clinical Education, in conjunction with The Perelman School of Medicine at the University of Pennsylvania and IBA, the leading proton beam therapy solutions manufacturer, involves oncologists gaining practical experience in Penn’s Roberts Proton Therapy Center – one of the world’s leading centres of proton therapy research and expertise.